Limflow System News Today

01.11.2023 - LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that it has entered into a definitive ...

Announces Q3 2023 Financial Results Inari to Host Conference Call Today at 1:30 P.M PT / 4:30 P.M. ET IRVINE, Calif., Nov. 01, 2023 -- Inari Medical, Inc. , a medical device company with a...

EQS Newswire / 18/09/2023 / 11:40 CET/CEST SINGAPORE - Media OutReach - 18 September 2023 - M&L Healthcare, in its first major MedTech investment, has announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of the LimFlow System - a revolutionary thera...

New therapeutic option has potential to reduce rate of major limb amputation in US

Revolutionary limb saving procedure set to benefit patients with Chronic Limb-Threatening Ischemia, typically caused by Type 2 DiabetesSINGAPORE - Media OutReach - 15 September...

The transcatheter stent-like device diverts arterial flow to the lower-extremity venous system to treat no-option patients with chronic limb-threatening ischemia.

LimFlow announced today that the FDA approved its LimFlow System for treating chronic limb-threatening ischemia (CLTI).

Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.

PROMISE II Trial Met Primary Endpoint Therapy Demonstrates 76% Limb Salvage in Patients with Chronic Limb-Threatening Ischemia Who Otherwise Faced Amputation LimFlow SA, a pioneer in the

LimFlow said new study results demonstrated statistically significant survival with its chronic limb-threatening ischemia (CLTI) treatment.